Study of biotransformation of new selective carbonic anhydrase II inhibitor 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide

The aim of the study was to determine biotransformation products of a new selective carbonic anhydrase II inhibitor – 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide.

Materials and methods. The study was conducted on 3 Wistar rats and 3 rabbits of the Soviet Chinchilla breed. The suspension of the drug was administered intraperitoneally to rats at a dosage of 20 mg/kg, to rabbits - at a dosage of 1.6 mg/kg. The animal blood samples were collected before the administration and 1, 2, 4, 24 h after. Urine sampling was also performed in the rats before the administration and in the intervals of 0–4, 4–8, 8–24 h after. The identification of metabolites in blood, urine and plasma was carried out using HPLC-MS/MS. Poroshell 120 C 18 column (50×3.0 mm, 2.7 µm) with a Zorbax Eclipse Plus C18 pre-column (12.5×2.1 mm, 5.0 µm) was used for the chromatographic separation. The assumed metabolites were synthesized, their structure was confirmed by the NMR spectroscopy method and a high-resolution mass spectrometry. The obtained substances were compared with the substances identified in biological fluids by retention time, the main MRM-transitions and mass spectra.

Results. The N-hydroxymetabolite was revealed in the analyses of plasma, blood and urine samples which had been formed by the addition of an oxygen atom to the drug molecule. Chromatographic peaks of this compound were identified at the MRM-transitions of 255→159, 255→117, 255→89 m/z at the 7.2nd min of the analysis. The N-oxide of 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide and N-hydroxy-4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide were synthesized; potentially, they could have been obtained during the biotransformation. During the confirmatory HPLC-MS/MS tests based on the coincidence of the retention times, the main MRM transitions and mass spectra, the ratio of the peak areas at the identified metabolite it was established that an N-hydroxy derivative. Chromatographic peaks of the N-oxide detected in the analysis of the model mixtures of the standard substance at the MRM-transitions of 255→175, 255→133, 255→89 m/z at the retention time of 5.43 min, were absent in the animal samples.

Conclusion. The studied drug is metabolized to form a single metabolite of N-hydroxy-4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide. This compound was found in freshly collected samples of biological fluids of both animal species. The structure of the metabolite was confirmed by the HPLC-MS/MS-method by comparison with the synthesized standard substance.

1. Efimova JA, Shetnev AA, Gasilina OA. Korsakov MK. The efficient route for the synthesis of 4-(2-methyl-1,3-oxazole-5- yl)-benzenesulfonamide – a promising new generation antiglaucoma agent. Butlerov Communications. 2022;72(12):15–20. DOI: 10.37952/ROI-jbc-01/22-72-12-15. Russian

2. Ivanovsky SA, Veselova VN, Shetnev AA, Korsakov MK. Development and validation of a methodology for the quantitative determination of Oxazopt API. Butlerov Communications. 2022;72(12):139–46. DOI: 10.37952/ROI-jbc-01/22-72-12-139. Russian

3. Ferraroni M, Luccarini L, Masini E, Korsakov M, Scozzafava A, Supuran CT, Krasavin M. 1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads. Bioorg Med Chem. 2017;25(17):4560-5. DOI: 10.1016/j.bmc.2017.06.054

4. Krasavin M, Korsakov M, Dorogov M, Tuccinardi T, Dedeoglu N, Supuran CT. Probing the ‘bipolar’ nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Eur J Med Chem. 2015 Aug 28;101:334-47. DOI: 10.1016/j.ejmech.2015.06.022

5. Aladysheva ZhI, Belyaev VV, Beregovykh VV, Brkich GE, Greibo SV, Demina NB, Dzhurko YuA, Ivanovsky SA, Nikolenko NS, Komissarova VA, Korsakov MK, Lavrentieva LI, Meshkovsky AP, Miroshnikov AE, Onegin SV, Parfenov AA, Pozdnyakov NO, Poroikov VV, Pyatigorskaya NV, Pyatigorsky AM, Rakov AA, Sidorov AV, Spitsky OR, Trubnikov AA, Khokhlov AA, Khokhlov AL, Chikina IV, Shabalina MM, Shabrov VN, Shitov LN., Yaichkov II. Industrial Pharmacy: The Way to Create a Product: Monograph. Khokhlov AL, Pyatigorskaya NV, editors. Moscow: The Russian Scientific Academy; 2019, 394 p. Russian

6. Alsibaee AM, Aljohar HI, Attwa MW, Abdelhameed AS, Kadi AA. Investigation of fenebrutinib metabolism and bioactivation using ms3 methodology in ion trap LC/MS. Molecules. 2023;28(10):4225. DOI: 10.3390/molecules28104225

7. Geburek I, Schrenk D, These A. In vitro biotransformation of pyrrolizidine alkaloids in different species: part II-identification and quantitative assessment of the metabolite profile of six structurally different pyrrolizidine alkaloids. Arch Toxicol. 2020;94(11):3759-74. DOI: 10.1007/s00204-020-02853-9

8. Trawiński J, Wroński M, Gawlik M, Skibiński R. Identification of the new metabolite of nebivolol using liquid chromatography coupled with high-resolution mass spectrometry and chemometrics. Molecules. 2022;27(3):763. doi: 10.3390/molecules27030763

9. Peeters L, Vervliet P, Foubert K, Hermans N, Pieters L, Covaci A. A comparative study on the in vitro biotransformation of medicagenic acid using human liver microsomes and S9 fractions. Chemico-Biological Interactions. 2020;328:109192. DOI: 10.1016/j.cbi.2020.109192

10. Boyce M, Favela KA, Bonzo JA, Chao A, Lizarraga LE, Moody LR, Owens EO, Patlewicz G, Shah I, Sobus JR, Thomas RS, Williams AJ, Yau A, Wambaugh JF. Identifying xenobiotic metabolites with in silico prediction tools and LCMS suspect screening analysis. Front Toxicol. 2023;5:1051483. DOI: 10.3389/ftox.2023.1051483

11. Chen WH, Chiu CH, Farn SS, Cheng KH, Huang YR, Lee SY, Fang YC, Lin YH, Chang KW. Identification of the hepatic metabolites of flumazenil and their kinetic application in neuroimaging. Pharmaceuticals (Basel). 2023;16(5):764. DOI: 10.3390/ph16050764

12. Walczak M, Suraj-Prażmowska J, Kuś K, Kij A, Groszek G. A preliminary metabolites identification of a novel compound with β-adrenolytic activity. Pharmacol Rep. 2021;73(5):1373–89. DOI: 10.1007/s43440-021-00273-9

13. Al-Shakliah NS, Attwa MW, Alrabiah H, Kadi AA. Identification and characterization of in vitro, in vivo and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry. Analytical Methods. 2021;13(3):399–410. DOI: 10.1039/d0ay02106g

14. Belinskaia DA, Savelieva EI, Karakashev GV, Orlova OI, Leninskii MA, Khlebnikova NS, Shestakova NN, Kiskina AR. Investigation of bemethyl biotransformation pathways by combination of LC-MS/HRMS and in silico methods. Int J Mol Sci. 2021;22(16):9021. DOI: 10.3390/ijms22169021

15. Levina IS, Nazarov AK, Nazarov GV, Kulikova LE, Kuznetsov YV, Dmitrenok AS, Minin DV, Aksenov AV, Zavarzin IV. In vivo study on biotransformation of pentacyclic analogs of progesterone: Identification of their metabolites by HPLC-MS method. J Steroid Biochem Mol Biol. 2019;194:105436. DOI: 10.1016/j.jsbmb.2019.105436

16. Sun Z, Yang J, Liu L, Xu Y, Zhou L, Jia Q, Shi Y, Du X, Kang J, Zuo L. Pharmacokinetics and metabolite profiling of trepibutone in rats using ultra-high performance liquid chromatography combined with hybrid quadrupole-orbitrap and triple quadrupole mass spectrometers. Front Pharmacol. 2019;10:1266. DOI: 10.3389/fphar.2019.01266

17. Zhu C, Wan M, Cheng H, Wang H, Zhu M, Wu C. Rapid detection and structural characterization of verapamil metabolites in rats by UPLC-MSE and UNIFI platform. Biomed Chromatogr. 2020;34(1):e4702. DOI: 10.1002/bmc.4702

18. Lee K, Lee JY, Lee K, Jung CR, Kim MJ, Kim JA, Yoo DG, Shin EJ, Oh SJ. Metabolite profiling and characterization of LW6, a novel HIF-1α inhibitor, as an antitumor drug candidate in mice. Molecules. 2021;26(7):1951. DOI: 10.3390/molecules26071951

19. Reddy GN, Laltanpuii C, Sonti R. Review on in vivo profiling of drug metabolites with LC-MS/MS in the past decade. Bioanalysis. 2021;13(22):1697–722. DOI: 10.4155/bio-2021-0144

20. Alseekh S, Aharoni A, Brotman Y, Contrepois K, D’Auria J, Ewald J, C Ewald J, Fraser PD, Giavalisco P, Hall RD, Heinemann M, Link H, Luo J, Neumann S, Nielsen J, Perez de Souza L, Saito K, Sauer U, Schroeder FC, Schuster S, Siuzdak G, Skirycz A, Sumner LW, Snyder MP, Tang H, Tohge T, Wang Y, Wen W, Wu S, Xu G, Zamboni N, Fernie AR. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat Methods. 2021;18(7):747–56. DOI: 10.1038/s41592-021-01197-1

21. Khokhlov AL, Ryska M, Kukes VG, Pisachkova M, Pechena M, Yavorsky AN, Shitov LN, Dzhurko YuA, Romodanovsky DP, Shitova AM, Korsakov MK, Lileeva EG, Khokhlov AA, Pozdnyakov NO, Miroshnikov AE, Voronina EA, Rybachkova YuV, Yaichkov II. Modern approaches to conducting bioanalytical research in the creation of drugs: monograph. Khokhlov AL, editor; Moscow: The Russian Scientific Academy; 2018, 243 p. Russian

22. Lo Faro AF, Tini A, Gottardi M, Pirani F, Sirignano A, Giorgetti R, Busardò FP. Development and validation of a fast ultra-high-performance liquid chromatography tandem mass spectrometry method for determining carbonic anhydrase inhibitors and their metabolites in urine and hair. Drug Test Anal. 2021;13(8):1552–60. DOI: 10.1002/dta.3055

23. Dhandar AG, Chaudhari SR, Ganorkar SB, Patil AS, Surana SJ. Mini-Review on bioanalytical estimation of brinzolamide. Curr Pharmaceutic Analysis. 2022;18(3):265–72. DOI: 10.2174/1573412917666210812103414

24. Mandour A, Nabil N, Zaazaa HE, Abdelkawy M. Review on analytical studies of some pharmaceutical compounds containing heterocyclic rings: brinzolamide, timolol maleate, flumethasone pivalate, and clioquinol. Future J Pharmaceutic Sci. 2020;6:52. DOI:10.1186/s43094-020-00068-4

25. Begou O, Drabert K, Theodoridis G, Tsikas D. GC-NICI-MS analysis of acetazolamide and other sulfonamide (R-SO2-NH2) drugs as pentafluorobenzyl derivatives [R-SO2-N(PFB)2] and quantification of pharmacological acetazolamide in human urine. J Pharm Anal. 2020;10(1):49–59. DOI: 10.1016/j.jpha.2019.11.006

26. Karnakova PK, Komarov TN, Archakova OA, Shchelgacheva DS, Aleshina AA, Bagaeva NS, Karpova PA, Shohin IE. Simultaneous determination of candesartan and hydrochlorothiazide in human plasma by HPLC-MS/MS. Drug Development & Registration. 2021;10(4):177–89. DOI: 10.33380/2305-2066-2021-10-4-177-189. Russian

27. Haque A, Iqbal M, Alamoudi MK, Alam P. A Selective and accurate LC-MS/MS method for simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. Separations. 2023;10:119. DOI: 10.3390/separations10020119

28. Ma Y, Modrzynski JJ, Yang Y, Aamand J, Zheng Y. Redox-dependent biotransformation of sulfonamide antibiotics exceeds sorption and mineralization: Evidence from incubation of sediments from a reclaimed water-affected river. Water Res. 2021;205:117616. DOI: 10.1016/j.watres.2021.117616

29. Vree TB, Hekster YA, Tijhuis MW. Metabolism of Sulfonamides. Antibiotics and Chemotherapy. Pharmacokinetics of Sulfonamides Revisited. 1985;34:5–65. DOI: 10.1159/000410271